^
Association details:
| Biomarker: | PGR negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Published date:
12/22/2021
Excerpt:
Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included....The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively....Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024)....We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.
DOI:
10.1080/07357907.2021.2017952
